Alnylam Appoints Dr. Vicki L. Sato as Director; Appointment of Industry Leader Brings Rich Experience in Drug Discovery and Development to Board.CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals Alnylam Pharmaceuticals Inc. (NYSE: ALNY), a biopharmaceutical company, engages in the development and commercialization of therapeutic products based on RNA interference (RNAi) in the United States. , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the election of Vicki L. Sato, Ph.D. to its Board of Directors. Dr. Sato was formerly President of Vertex Pharmaceuticals Vertex Pharmaceuticals is a biotechnology company with activities spanning the length of the pharmaceutical product pipeline, from target identification through to clinical trials and marketing. from 2000 to 2005. Prior to her position as President, she served as the company's Chief Scientific Officer and Chair of the Scientific Advisory Board. Dr. Sato is credited with establishing Vertex as a leading innovator in small molecule drug discovery and development, and under her leadership, the company built a robust pipeline of product candidates in the areas of viral disease, autoimmune diseases Autoimmune diseases A group of diseases, like rheumatoid arthritis and systemic lupus erythematosus, in which immune cells turn on the body, attacking various tissues and organs. Mentioned in: Complement Deficiencies, Premature Menopause , and cancer, as well as a portfolio of collaborative partnerships. Prior to joining Vertex, she held numerous leadership positions at Biogen Inc. (now BiogenIdec), including Vice President of Research. Dr. Sato served as both Assistant and Associate Professor in the Department of Biology at Harvard University Harvard University, mainly at Cambridge, Mass., including Harvard College, the oldest American college. Harvard College Harvard College, originally for men, was founded in 1636 with a grant from the General Court of the Massachusetts Bay Colony. from 1976 to 1983, and received her Bachelor, Master, and Doctoral degrees from Harvard University. Dr. Sato currently serves as a member of both the Board of Directors and Scientific Advisory Board of Infinity Pharmaceuticals, and is a member of the Board of Directors of PerkinElmer, Inc. "Vicki is widely recognized as one of the biotechnology industry's leading executives, instrumental in building top-tier companies such as Biogen and Vertex, where she led the translation of cutting-edge science into products," said John Maraganore, Ph.D., President and Chief Executive Officer of Alnylam. "Given that we have recently advanced our pipeline into the clinic, the addition of Vicki to our team comes at a highly opportune op·por·tune adj. 1. Suited or right for a particular purpose: an opportune place to make camp. 2. Occurring at a fitting or advantageous time: an opportune arrival. time in the growth of our business. Indeed, we believe that her broad and deep expertise in the research and development of innovative medicines will bring a unique dimension to the Board as we continue to build Alnylam as a leading biopharmaceutical company." Alnylam also announced that John Berriman is resigning from the Board of Directors of the company. "We are grateful to John, as one of our early venture investors, for his contributions in bringing our company to this important stage of its growth," continued Dr. Maraganore. "We wish him all the best in his future endeavors." Alnylam also announced that Patricia Allen, the company's Vice President of Finance, has been named as the Treasurer and an executive officer of the company, effective January 1, 2006. About Alnylam Alnylam is a biopharmaceutical company developing novel therapeutics based on a breakthrough in biology known as RNA interference RNA interference n. A process in which the introduction of double-stranded RNA into a cell inhibits the expression of genes. , or RNAi. The company, founded in 2002 by scientific pioneers in the field of RNAi, maintains a leadership position in fundamental patents, technology, and know-how relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc RNAi. Alnylam is applying its expertise in RNAi to address multiple therapeutic opportunities that cannot effectively be addressed with small molecules or antibodies, the two current major classes of drugs. The company's expertise in designing and optimizing RNAi therapeutics has enabled Alnylam to form major alliances with leading companies including Merck, Medtronic, and Novartis. The company's global headquarters are in Cambridge, Massachusetts This article is about the city of Cambridge in Massachusetts. For the English university town, see Cambridge, England. For other places, see Cambridge (disambiguation). Cambridge, Massachusetts is a city in the Greater Boston area of Massachusetts, United States. , with an additional operating unit operating unit A type of operating company that engages in transactions with outsiders and that is owned by another business. For example, in 1995 the stockholders of Capital Cities/ABC approved a $19 billion merger with the Walt Disney Company, whereupon in Kulmbach, Germany. For more information, please visit www.alnylam.com. Alnylam Forward-Looking Statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. Various statements in this release concerning our future expectations, plans and prospects, constitute forward-looking statements for the purposes of the safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. provisions under The Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: our approach to discover and develop novel drugs, which is unproven and may never lead to marketable products; our ability to obtain additional funding to support our business activities; our dependence on third parties for development, manufacture, marketing, sales and distribution of our products; the successful development of products, all of which are in early stages of development; obtaining regulatory approval for products; competition from others using technology similar to ours and others developing products for similar uses; obtaining, maintaining and protecting intellectual property utilized by our products; our dependence on collaborators; and our short operating history; as well as those risks more fully discussed in the "Certain Factors That May Affect Future Results" section of our most recent quarterly report on Form 10-Q Form 10-Q See 10-Q. on file with the Securities and Exchange Commission. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We do not assume any obligation to update any forward-looking statements. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion